DNS-7801 vs. Placebo in Parkinson's Disease
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Parkinson's Disease
In brief
This is a randomized, double-blind, two-part placebo-controlled parallel group outpatient treatment study that will utilize standard Parkinson's Disease measures to evaluate the effect of DNS-7801
Key facts
- Study ID
- NCT03306329
- Run by
- Dart NeuroScience, LLC
- People needed
- 5
- Starts
- 2017-09-13
- Expected to finish
- 2017-12-31
- Last updated by the study team
- 2018-02-01
Who can join
Age: 30 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Collaborative Neuroscience Network — Long Beach, California, United States
- SC3 Research — Pasadena, California, United States
- Rocky Mountain Movement Disorders Center — Englewood, Colorado, United States
- Parkinsons Disease and Movement Disorders Center of Boca Raton — Boca Raton, Florida, United States
- University of South Florida Parkinson's Disease and Movement Disorders Center — Tampa, Florida, United States
- Quest Research Institute — Farmington, Michigan, United States
- Washington University — St Louis, Missouri, United States
- The Neurological Institute PA — Charlotte, North Carolina, United States
- Premier Clinical Research — Spokane, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.